Advocating for Patients: Letter to the FDA on RP1 Treatment Access
Published:
09/05/2025
Categories:
Hundreds of patients, families, and friends have shared their stories with AIM at Melanoma about the urgent need for access to RP1+nivolumab. We are grateful to everyone who contributed. Yesterday, along with several other melanoma organizations, we sent a letter to the FDA urging them to make RP1 available while remaining regulatory issues are addressed.
The full letter is embedded below for your reference. Click on the image to enlarge it, or download the PDF using the link beneath the letter.
Recent Posts
Jul. 06, 2026
How Melanoma Changed Adam Harper’s Perspective on Life
Jun. 26, 2026
FDA Accepts Review of RP1 for Advanced Melanoma; Decision Expected August 2026
Jun. 23, 2026
Insights from the 2026 American Academy of Dermatology (AAD) Annual Practice Safe Sun Survey
Jun. 09, 2026
The FDA Just Approved a New Sunscreen Ingredient—What It Means for Patients with Skin Cancer, Survivors, and the General Public
Jun. 09, 2026